Search Results
Your search for early matches 10107 pages
Showing 3401 - 3450Many Reasons to ‘Geriatricize’ Your Oncology Practice: Research Updates From ASCO20
“Older adults form the majority of patients with cancer.” For more than 3 decades now, almost every article, presentation, or discussion related to cancer and aging started with this statement. As I entered the field of geriatric oncology, I thought that by simply stating this fact, everyone would...
New Breast Cancer Agents and Concurrent Radiation: Risk or Benefit?
Most of the newer systemic treatments for breast cancer can be safely and effectively paired with radiation therapy—although there are some exceptions, according to Mylin A. Torres, MD, the Louisa and Rand Glenn Family Chair in Breast Cancer Research and Associate Professor of Radiation Oncology at ...
Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...
With the Goal of Curing Cancer, Ezra M. Greenspan, MD, Helped Usher in the Modern Era of Chemotherapy
Born in Brooklyn on April 4, 1919, Ezra M. Greenspan, MD, did not stray far from his birthplace, spending most of his 5-decade medical career in New York. After graduating from New York University School of Medicine in 1942, he was accepted into the house training program at Mount Sinai Hospital...
Karmanos Receives $630,000 CATCH-UP Grant to Recruit Minority, Rural Patients to Clinical Trials
Researchers at the Barbara Ann Karmanos Cancer Institute have secured a 1-year, $630,000 grant from the National Cancer Institute (NCI) to help support the Institute’s clinical trials, which target underserved populations in Detroit and in the rural areas that Karmanos serves. The NCI P30 Cancer...
Early Cancer Experience Plants the Seed for a Career in Oncology to Grow for Joyce F. Liu, MD, MPH
As a young girl growing up in central New Jersey, Joyce F. Liu, MD, MPH, a medical oncologist specializing in gynecologic cancers at Dana-Farber Cancer Institute, Boston, dreamed of becoming an astronaut. However, she realized her fear of heights and propensity for motion sickness didn’t jive with...
Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies
Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen...
Phase III NALA Trial Meets Primary Endpoint in Previously Treated HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Cristina Saura, MD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with the irreversible pan-HER tyrosine kinase inhibitor neratinib plus...
Corticosteroids Improve Survival in Critically Ill Patients With COVID-19, According to International Trial
In a demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in 8 countries to find that inexpensive, widely available steroids may improve the odds that very sick patients with COVID-19 will survive the illness. The findings were made through the Randomized...
Expert Point of View: David Scott, MBChB, PhD
“In 2015, papers showed that ctDNA could suggest relapse noninvasively in serial plasma samples. In those studies, ctDNA was positive prior to relapse detected by computed tomography scans,” explained session moderator David Scott, MBChB, PhD, of the Center for Lymphoid Cancer, BC Cancer,...
Applications of Circulating Tumor DNA Liquid Biopsy Continue to Expand in Lymphomas
Liquid biopsies using circulating tumor DNA (ctDNA) have the potential to personalize medicine for patients with lymphoma, going beyond traditional markers and risk factors to provide dynamic assessments over time. Expanded applications of ctDNA liquid biopsy beyond diagnosis include early response ...
Disparities and Incidence of Late Effects of Treatment for AYA Lymphoma Survivors
The late effects of adolescent and young adults (AYA) with lymphomas are considerable and have not been given much attention, according to Theresa Keegan, MD, of the University of California at Davis. “Lymphoma is one of the most commonly occurring malignancies in AYAs,” she stated. “The 5-year...
Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in the metastatic setting with palbociclib plus endocrine therapy did not translate into the earlier adjuvant setting for...
Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this...
Efforts to Broaden Eligibility Criteria for Clinical Trials Seek to Include More Racial and Ethnic Minority Patients
A review of the 2019 Drug Trials Snapshots Report1 from the U.S. Food and Drug Administration (FDA) showed that although female participation in clinical trials grew to 72% from 56% in the FDA’s 2018 Drug Trials Snapshots Report,2 ethnic minority participation in clinical trials actually declined...
AACR Releases 10th Edition of Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 10th edition of its annual Cancer Progress Report. The report highlights how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is...
Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
The challenge in treating patients with borderline resectable pancreatic cancer is how to render tumors resectable and how to achieve the negative surgical margins that enhance long-term survival odds. Fortunately, neoadjuvant chemotherapy is helping to achieve these important goals, according to...
Early-Phase Trial Explores Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Genitourinary Malignancies
In a phase I trial reported in the Journal of Clinical Oncology, Andrea B. Apolo, MD, and colleagues found that the combination of cabozantinib and nivolumab, as well as the combination of cabozantinib/nivolumab plus ipilimumab, produced durable responses in patients with metastatic urothelial...
Joint Statement From the AMA, AHA, and ANA on U.S. Coronavirus Death Toll
Today, the American Medical Association (AMA), American Hospital Association (AHA), and American Nurses Association (ANA) released a joint statement on the amount of deaths caused by the coronavirus in the United States. Today we mark a somber milestone as more than 200,000 people in the United...
Stephen R.D. Johnston, MD, PhD, on Early Breast Cancer: Abemaciclib in High-Risk Disease
Stephen R.D. Johnston, MD, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase III study findings from the global monarchE trial, which showed that when added to standard adjuvant endocrine therapy, abemaciclib is the first CDK4/6 inhibitor to improve invasive disease–free survival in...
New Report Focuses on Cancer Statistics in Adolescents and Young Adults
A new report examining cancer in adolescents and young adults (AYAs, defined as diagnoses occurring between the ages of 15 and 39) provides updated estimates of the contemporary cancer burden in this age group, with predictions that 89,500 cases and 9,270 deaths will occur in this group in 2020 in...
Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin
Andreas Schneeweiss, MD, of the Heidelberg University Hospital and German Cancer Research Center, discusses phase III survival data from the GeparOcto trial, which compared the neoadjuvant chemotherapy intense dose-dense EPC (epirubicin, paclitaxel, and cyclophosphamide) with weekly paclitaxel and...
Abemaciclib Plus Endocrine Therapy May Reduce Recurrence in Early Breast Cancer: monarchE Trial
For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has improved outcomes in patients with early breast cancer when combined with standard endocrine therapy, Stephen Johnston, MD, PhD, and colleagues reported at the ESMO Virtual Congress 2020 (Abstract LBA5_PR)....
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...
World Gynecologic Oncology Awareness Day (World GO Day): September 20
Patient advocates and medical professionals in more than 20 countries have come together for the second annual World Gynecologic Oncology Day (World GO Day), taking place today, September 20. A project of the European Society of Gynaecological Oncology (ESGO) and the European Network of...
KRAS G12C Inhibitor Shows Activity in Solid Tumors, Lung Cancer
In a phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRAS G12C inhibitor sotorasib (AMG 510) showed manageable toxicities and durable clinical benefits. Results from the trial were published in The New England Journal of Medicine, and data from the ...
Effects of the COVID-19 Pandemic on Cancer Care, Provider Well-Being
Delays and cancellation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to the coronavirus have generated a backlog in oncology care and research. The threat of delayed diagnoses looms while oncology professionals face burnout, according to new studies...
ESMO 2020: Access to Treatments and Trials Varies Widely for Patients With Cancer Across Europe
Access to cancer treatments is highly unequal across Europe, both for new drugs in development (due to disparities in access to clinical trials) and for currently approved drugs (due to disparities in health-care spending by different countries), according to results from two studies being...
Caring for Undocumented Patients With Cancer
There are approximately 25 million foreign-born immigrants living in the United States, which is more than 13% of the nation’s total population. Of these individuals, it is estimated that about 11 million are undocumented; by far, the largest group of this immigrant undocumented population is...
Inaugural AACR Cancer Disparities Progress Report Released
The American Association for Cancer Research (AACR) released its inaugural Cancer Disparities Progress Report 2020, which found that while overall cancer death rates are declining and the number of survivors is reaching record highs, progress against cancer is not benefiting everyone equally, with...
Meta-analysis of Duration of Adjuvant Trastuzumab in Early Breast Cancer
In individual participant data and trial-level meta-analyses reported in JAMA Network Open, Gulia et al found that disease-free survival with adjuvant trastuzumab given for less than 1 year was noninferior to 1 year of trastuzumab therapy in patients with early breast cancer. In addition, the...
Enthusiastic Response to Novel Therapies on the Horizon in Multiple Myeloma
Clinicians who treat multiple myeloma can anticipate a host of new treatments: melflufen, cereblon E3 ligase (CEL) modulators, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Kenneth C. Anderson, MD, Director of the Jerome Lipper Multiple...
Dr. Kantarjian Shares His Thoughts on Optimizing the Treatment of Adults With ALL
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor and...
Combination Immunotherapy Benefits Subset of Patients With Advanced Prostate Cancer
Results from a phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti–CTLA-4) plus nivolumab (anti–PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer, an...
Role of Inherited GATA3 Variant in Response to Treatment, Disease Relapse in Pediatric ALL
Research published by Zhang et al in the Journal of the National Cancer Institute showed that an inherited variation in the GATA3 gene strongly influences early response to chemotherapy and is linked to relapse in children with acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD)...
Roger H. Herzig, MD, Pioneer in the Treatment of Leukemia, Dies at Age 74
More than 5 decades ago, the concept of bone marrow transplantation to treat humans with leukemia was met with varying degrees of skepticism and countless clinical failures. Yet, over those same decades, bone marrow transplantation was transformed from an insurmountable therapeutic option used in a ...
Theodore Laetsch, MD, Joins Children’s Hospital of Philadelphia to Launch Very Rare Malignant Tumors Program
Pediatric hematologist-oncologist Theodore Laetsch, MD, has joined the Division of Oncology at Children’s Hospital ofPhiladelphia (CHOP), where he will launch a cutting-edge Very Rare Malignant Tumors Program that will seek to develop new treatments for children with rare and complex tumors. In...
Cervical Cancer Screening and Prevention in Low- and Middle-Income Countries: 2020
Cervical cancer is a worldwide public health problem. The incidence of the disease is particularly high in low- and middle-income countries, where low coverage of prevention strategies and high risk of infection persist. To reduce morbidity and mortality, improved screening and prevention are...
Seattle Cancer Care Alliance Expands South Lake Union Campus
Seattle Cancer Care Alliance (SCCA) announced the beginning of construction on its South Lake Union campus to add a six-story, 150,000 square-foot outpatient cancer treatment clinic. The largest single construction project in SCCA history, the new building will feature a patient-centered design,...
Research Pioneer Marc L. Citron, MD, Establishes Grants Through Conquer Cancer
“Ask any doctor why he or she enters medicine and the answer will likely be the same,” said Marc L. Citron, MD. “People become doctors to help patients...but to deliver the moments that matter to patients—to extend their lives and give quality to their days—doctors rely on new research.” In 2003,...
Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers
Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...
Global Oncology Young Investigator Award: Early Support Improves Cancer Care Around the World
Global oncology refers to the application of the concepts of global health to cancer and implies an approach to the practice of oncology that acknowledges the reality of limited resources in parts of the world. The Global Oncology Young Investigator Award (YIA) from ASCO and Conquer Cancer, the...
Fitness-Based Treatment of Older Adults With Multiple Myeloma Who Are Transplant-Ineligible: The Changing Landscape
Multiple myeloma is a malignant clonal plasma cell malignancy that primarily affects older adults. Although therapeutic advances have led to improvements in disease-specific and overall survival over the past decade, age-related survival disparities continue to exist. The higher prevalence of...
Setting an Ambitious Path to Ensure Health Equity for All Patients With Cancer
In keeping with her Presidential theme of “Equity: Every Patient, Every Day, Everywhere,” in July, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, announced the Society was joining forces with the Association of Community Cancer Centers (ACCC) to increase racial and ethnic minority participation...
Avelumab in Maintenance Treatment of Urothelial Carcinoma
On June 30, 2020, avelumab was approved for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.1,2 Supporting Efficacy Data Approval was based on findings in the randomized, multicenter, ...
Art in Oncology: How Patients Add Life to Their Days
The ASCO Post is pleased to reproduce installments of “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer. They include narratives, topical essays, historical...
High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
Primary Prevention Strategies for Avoiding Cardiotoxicity in Patients With Cancer: A Growing Area of Research
Cancer is not for the faint of heart, and sometimes neither is the treatment, according to information presented during the ASCO20 Virtual Education Program.1 Approximately 30% of patients who receive cancer therapy will have cardiovascular complications.2 What’s more, in anthracycline-treated...
Update on Novel Immunotherapies for Plasma Cell Disorders
In this installment of The ASCO Post’s Hematology Expert Review, we take a closer look at the monoclonal antibody targeting CD38, daratumumab, in the treatment of amyloid light chain (AL) amyloidosis and resistant multiple myeloma as well as the antibody-drug conjugate belantamab mafodotin-blmf,...
Personalized Medicine Meets Geriatric Oncology: Tailoring Oncologic Care for Older Adults
The ASCO20 Virtual Scientific Program was a landmark year for the field of geriatric oncology, featuring more than 300 research abstracts that presented data on older adults with cancer. Here, we discuss several high-impact studies investigating interventions that modify outcomes for this patient...
